CSI Market
Sign In | Register

Northwest Biotherapeutics Inc (NWBO) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access NWBO quarterly Cash Flow →
The data below summarizes Northwest Biotherapeutics Inc's cash flow activity from Dec 31 2021 to Dec 31 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-60.16
Depreciation & amortization2.06
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring Costs0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Environmental Expense and Liabilities0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation1.21
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt17.40
Derivative Gain Loss On Derivative Net0.15
Accrued Interest Converted To Preferred Stock-
Accreted Interest On Convertible Promissory Note-
Stock And Warrants Issued For Services And Other Expenses-
Inducement Expenses-
Valuation Of Reclassified Equity Contracts-
Asset Impairment Loss And Gain Loss On Sale Of Properties-
Increase Decrease In Prepaid Expense And Other Current Assets-0.84
Deposits And Other Assets Noncurrent0.02
Reclass Of Redeemable Security To Equity-
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction-
Stock Based Compensation Related To Warrants Modification-
Adjustments To Additional Paid In Capital Reclassification-
Stock Issued During Period Value Conversion Of Convertible Securities-
Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received37.03
Debt Conversion Converted Instrument Associate Warrants-
Warrants Issued Associated With Convertible Notes Payable To Related Party-
Reclassification Of Accrued Interst To Subscription Receivable-
Operating Lease Right Of Use Asset Amortization Expense0.27
Warrant Modifications Associated With Convertible Notes Under Fair Value Option-
Increase Decrease In Operating Lease Liability0.09
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities7.75
Increase (Decrease) in Due to Related Parties, Current5.94
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-55.68
Discontinued operations0.00
Net Cash flow from Operating Activities-44.76
Investing Activities
Capital Expenditures-1.50
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments For Refund Of Security Deposit-
Refund Of Leashold Improvement Related To Uk Construction-
Refund Of V at Related To Uk Construction-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables-0.31
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-1.82
Financing Activities
Short-term debt Net12.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-1.27
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock19.34
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net19.26
Proceeds From Shares Payable-
Proceeds From Exercise Of Stock Options And Warrants-
Proceeds From Issuance Of Capital Stock And Warrants-
Preferred Stock Redemption Fee-
Proceed From Deferred Offering Cost Releated To Convertible Note-
Proceeds From Convertible Notes Payable Related Parties-
Proceeds From Notes Payable Related Parties-
Proceeds From Issuance Of Convertible Promissory Note And Warrants Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock Over Allotment Rights-
Payment Of Warrants Excercise Offering Cost-
Proceeds From Private Offering-
Proceeds From Subscription Receivable-
Proceeds From Investors-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities49.33
Effect of exchange rate on cash flow-1.88
Discontinued operations0.00
Free Cash Flow-46.27
Total Cash Flow0.87
4 historic quarters locked

Sign in to unlock the full Northwest Biotherapeutics Inc cash flow history.

Sign In Create Free Account

About Northwest Biotherapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-043806

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License